Literature DB >> 17148592

Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse.

Benny J Chen1, Divino Deoliveira, Xiuyu Cui, Ngocdiep T Le, Jessica Son, John F Whitesides, Nelson J Chao.   

Abstract

Several groups, including our own, have independently demonstrated that effector memory T cells from non-alloantigen-primed donors do not cause graft-versus-host disease (GVHD). In the current study, we further investigated whether this approach could be extended to all memory T cells, and we studied the underlying mechanisms. Neither total memory T cells nor purified central memory T cells were able to induce GVHD. Memory T cells were at least 3-log less potent than bulk T cells in mediating GVHD. As expected, memory T cells failed to elicit cytotoxicity and proliferated poorly against alloantigens in standard 5-day mixed-lymphocyte cultures. However, the proliferative responses of memory T cells were more comparable with those of bulk and naive T cells when the culture time was shortened. Moreover, the frequencies of IL-2-secreting cells measured by 42-hour enzyme-linked immunosorbent spot (ELISPOT) assay were similar among naive, memory, and bulk T cells. These data indicated that memory T cells are able to respond to alloantigens initially but fail to develop to full potential. The abortive immune response, which was mediated by non-alloantigen-specific memory T cells in response to alloantigens, may explain why memory T cells from unprimed and non-alloantigen-primed donors could not induce GVHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17148592      PMCID: PMC1852216          DOI: 10.1182/blood-2006-04-016410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation.

Authors:  Benny J Chen; Xiuyu Cui; Nelson J Chao
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

3.  Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation.

Authors:  Defu Zeng; Petra Hoffmann; Fengshuo Lan; Philip Huie; John Higgins; Samuel Strober
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

4.  Lineage relationship and protective immunity of memory CD8 T cell subsets.

Authors:  E John Wherry; Volker Teichgräber; Todd C Becker; David Masopust; Susan M Kaech; Rustom Antia; Ulrich H von Andrian; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

5.  Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model.

Authors:  Benny J Chen; Yanfei Chen; Xiuyu Cui; John M Fidler; Nelson J Chao
Journal:  Transplantation       Date:  2002-01-15       Impact factor: 4.939

6.  Memory CD4+ T cells do not induce graft-versus-host disease.

Authors:  Britt E Anderson; Jennifer McNiff; Jun Yan; Hester Doyle; Mark Mamula; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.

Authors:  Benny J Chen; Xiuyu Cui; Gregory D Sempowski; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

8.  Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset.

Authors:  Emmanuel Xystrakis; Isabelle Bernard; Anne S Dejean; Talal Alsaati; Philippe Druet; Abdelhadi Saoudi
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

9.  Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen.

Authors:  Richard L Hengel; Vishakha Thaker; Mark V Pavlick; Julia A Metcalf; Glynn Dennis; Jun Yang; Richard A Lempicki; Irini Sereti; H Clifford Lane
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  68 in total

1.  CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice.

Authors:  Jifeng Zhang; Brice E Barefoot; Wenjian Mo; Divino Deoliveira; Jessica Son; Xiuyu Cui; Elizabeth Ramsburg; Benny J Chen
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

Review 2.  Negative regulators in homeostasis of naïve peripheral T cells.

Authors:  Jaime F Modiano; Lisa D S Johnson; Donald Bellgrau
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Authors:  Xiaoou Zhou; Gianpietro Dotti; Robert A Krance; Caridad A Martinez; Swati Naik; Rammurti T Kamble; April G Durett; Olga Dakhova; Barbara Savoldo; Antonio Di Stasi; David M Spencer; Yu-Feng Lin; Hao Liu; Bambi J Grilley; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2015-05-14       Impact factor: 22.113

Review 4.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

5.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

6.  MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.

Authors:  Takero Shindo; Tae Kon Kim; Cara L Benjamin; Eric D Wieder; Robert B Levy; Krishna V Komanduri
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

7.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

8.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

9.  The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.

Authors:  Hidekazu Itamura; Takero Shindo; Isao Tawara; Yasushi Kubota; Ryusho Kariya; Seiji Okada; Krishna V Komanduri; Shinya Kimura
Journal:  JCI Insight       Date:  2016-07-07

10.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.